Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

403
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
403
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

670
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
670
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

800
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
800
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

1.9K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

1.3K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sudden hemodynamic collapse and biventricular dysfunction: What's your diagnosis?

Intensive care medicine·2026
Same author

How to optimize brain perfusion and prevent cerebral complications during extracorporeal life support.

Intensive care medicine·2026
Same author

Pharmacological treatment of cardiogenic shock.

Current opinion in critical care·2026
Same author

Novel treatment strategies in cardiogenic shock: an update on ongoing clinical trials.

Heart failure reviews·2026
Same author

Lactate in cardiogenic shock: pathophysiology, prognostic value, and clinical interpretation.

Annals of intensive care·2026
Same author

Comparison of norepinephrine with a combined non-catecholaminergic therapy in a porcine model of refractory cardiac arrest resuscitated with VA-ECMO.

Intensive care medicine experimental·2026

Related Experiment Video

Updated: Dec 19, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K

Vasopressor use in cardiogenic shock.

Bruno Levy1,2,3, Thomas Klein1,2,3, Antoine Kimmoun1,2,3

  • 1Service de Réanimation Médicale Brabois, CHRU Nancy, Pôle Cardio-Médico-Chirurgical.

Current Opinion in Critical Care
|June 4, 2020
PubMed
Summary

Vasopressor use in cardiogenic shock lacks robust evidence. Norepinephrine is a potential first-line agent, but vasopressor therapy should be temporary, bridging patients to recovery or advanced interventions.

More Related Videos

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

23.9K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.0K

Related Experiment Videos

Last Updated: Dec 19, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

23.9K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.0K

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Vasopressor therapy is crucial in managing cardiogenic shock.
  • Limited data exist on optimal vasopressor selection and effectiveness.
  • Side effects and lack of evidence hinder widespread use.

Purpose of the Study:

  • To review the current application of vasopressor therapy in cardiogenic shock.
  • To synthesize recent findings on vasopressor efficacy and safety.
  • To provide guidance on vasopressor use in this critical condition.

Main Methods:

  • Review of recent Cochrane analyses and randomized controlled trials (RCTs).
  • Analysis of meta-analyses on individual patient data.
  • Synthesis of current clinical recommendations and evidence.

Main Results:

  • Insufficient evidence supports superiority of any single vasopressor for mortality.
  • Norepinephrine may be preferred over epinephrine, especially post-myocardial infarction.
  • Vasopressin use is considered in specific cases like right ventricular failure with pulmonary hypertension.

Conclusions:

  • Norepinephrine is a reasonable first-line agent for restoring blood pressure.
  • Comparative outcome data remain sparse.
  • Vasopressor use should be a temporary measure, bridging to recovery or advanced therapies.